Literature DB >> 26342659

Cancer targeted therapeutics: From molecules to drug delivery vehicles.

Daxing Liu1, Debra T Auguste2.   

Abstract

The pitfall of all chemotherapeutics lies in drug resistance and the severe side effects experienced by patients. One way to reduce the off-target effects of chemotherapy on healthy tissues is to alter the biodistribution of drug. This can be achieved in two ways: Passive targeting utilizes shape, size, and surface chemistry to increase particle circulation and tumor accumulation. Active targeting employs either chemical moieties (e.g. peptides, sugars, aptamers, antibodies) to selectively bind to cell membranes or responsive elements (e.g. ultrasound, magnetism, light) to deliver its cargo within a local region. This article will focus on the systemic administration of anti-cancer agents and their ability to home to tumors and, if relevant, distant metastatic sites.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Active targeting; Integrated targeting; Passive targeting; Pharmacologic targeting; Targeted drug delivery

Mesh:

Substances:

Year:  2015        PMID: 26342659      PMCID: PMC5503194          DOI: 10.1016/j.jconrel.2015.08.041

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  184 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  Materials science: embedded shells decalcified.

Authors:  Catherine Picart; Dennis E Discher
Journal:  Nature       Date:  2007-08-23       Impact factor: 49.962

3.  Microvascular permeability of normal and neoplastic tissues.

Authors:  L E Gerlowski; R K Jain
Journal:  Microvasc Res       Date:  1986-05       Impact factor: 3.514

4.  A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy.

Authors:  A N Vis; A van der Gaast; B W G van Rhijn; T K Catsburg; C Schmidt; G H J Mickisch
Journal:  Cancer Chemother Pharmacol       Date:  2002-01-30       Impact factor: 3.333

Review 5.  Nanoparticle therapeutics for prostate cancer treatment.

Authors:  Vanna Sanna; Mario Sechi
Journal:  Maturitas       Date:  2012-02-17       Impact factor: 4.342

6.  Antibody targeting of liposomes: cell specificity obtained by conjugation of F(ab')2 to vesicle surface.

Authors:  T D Heath; R T Fraley; D Papahdjopoulos
Journal:  Science       Date:  1980-10-31       Impact factor: 47.728

Review 7.  Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects.

Authors:  Kazuo Maruyama
Journal:  Adv Drug Deliv Rev       Date:  2010-10-28       Impact factor: 15.470

8.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

Authors:  M E R O'Brien; N Wigler; M Inbar; R Rosso; E Grischke; A Santoro; R Catane; D G Kieback; P Tomczak; S P Ackland; F Orlandi; L Mellars; L Alland; C Tendler
Journal:  Ann Oncol       Date:  2004-03       Impact factor: 32.976

Review 9.  Paul Ehrlich's magic bullet concept: 100 years of progress.

Authors:  Klaus Strebhardt; Axel Ullrich
Journal:  Nat Rev Cancer       Date:  2008-05-12       Impact factor: 60.716

10.  Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer.

Authors:  S C White; P Lorigan; G P Margison; J M Margison; F Martin; N Thatcher; H Anderson; M Ranson
Journal:  Br J Cancer       Date:  2006-09-12       Impact factor: 7.640

View more
  21 in total

1.  A quantitative method for screening and identifying molecular targets for nanomedicine.

Authors:  Peng Guo; Jiang Yang; Diane R Bielenberg; Deborah Dillon; David Zurakowski; Marsha A Moses; Debra T Auguste
Journal:  J Control Release       Date:  2017-03-22       Impact factor: 9.776

Review 2.  Nanoplatforms for Targeted Stimuli-Responsive Drug Delivery: A Review of Platform Materials and Stimuli-Responsive Release and Targeting Mechanisms.

Authors:  Yuzhe Sun; Edward Davis
Journal:  Nanomaterials (Basel)       Date:  2021-03-16       Impact factor: 5.076

Review 3.  Emerging ways to treat breast cancer: will promises be met?

Authors:  Pouria Samadi; Sahar Saki; Fatemeh Karimi Dermani; Mona Pourjafar; Massoud Saidijam
Journal:  Cell Oncol (Dordr)       Date:  2018-09-27       Impact factor: 6.730

Review 4.  Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery: an update.

Authors:  Rafael R Castillo; Daniel Lozano; Blanca González; Miguel Manzano; Isabel Izquierdo-Barba; María Vallet-Regí
Journal:  Expert Opin Drug Deliv       Date:  2019-04-22       Impact factor: 6.648

5.  Epidermal growth factor receptor inhibitors trigger a type I interferon response in human skin.

Authors:  Daniela Lulli; Maria Luigia Carbone; Saveria Pastore
Journal:  Oncotarget       Date:  2016-07-26

Review 6.  Toward the Selection of Cell Targeting Aptamers with Extended Biological Functionalities to Facilitate Endosomal Escape of Cargoes.

Authors:  Kwaku D Tawiah; David Porciani; Donald H Burke
Journal:  Biomedicines       Date:  2017-08-24

7.  Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier.

Authors:  Yongjiu Lv; Jingjing Li; Huali Chen; Yan Bai; Liangke Zhang
Journal:  Int J Nanomedicine       Date:  2017-06-12

8.  A novel RGDyC/PEG co-modified PAMAM dendrimer-loaded arsenic trioxide of glioma targeting delivery system.

Authors:  Yanping Lu; Shunping Han; Hongyue Zheng; Rui Ma; Yuting Ping; Jiafeng Zou; Hongxia Tang; Yongping Zhang; Xiuling Xu; Fanzhu Li
Journal:  Int J Nanomedicine       Date:  2018-10-02

Review 9.  Biomimetic Membranes as a Technology Platform: Challenges and Opportunities.

Authors:  Claus Hélix-Nielsen
Journal:  Membranes (Basel)       Date:  2018-07-17

Review 10.  Utilizing Peptide Ligand GPCRs to Image and Treat Pancreatic Cancer.

Authors:  Gail L Matters; John F Harms
Journal:  Biomedicines       Date:  2018-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.